There are 453K new C. difficile infections (CDI) every year and 83K recurrent infections, yet there are no licensed vaccines against this important nosocomial pathogen. The current pipeline of clinical-stage vaccines consists of two toxin-based candidates and one phase 3 candidate, which is no longer being pursued. Although mathematical studies and computer-simulation models suggest that […]